Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 7
2004 3
2005 5
2006 11
2007 9
2008 41
2009 46
2010 51
2011 65
2012 55
2013 90
2014 88
2015 81
2016 105
2017 91
2018 122
2019 117
2020 125
2021 162
2022 194
2023 163
2024 58

Text availability

Article attribute

Article type

Publication date

Search Results

1,484 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial.
Gao P, Wang T, Wang D, Liebeskind DS, Shi H, Li T, Zhao Z, Cai Y, Wu W, He W, Yu J, Zheng B, Wang H, Wu Y, Dmytriw AA, Krings T, Derdeyn CP, Jiao L; CASSISS Trial Investigators. Gao P, et al. Among authors: wang h. JAMA. 2022 Aug 9;328(6):534-542. doi: 10.1001/jama.2022.12000. JAMA. 2022. PMID: 35943472 Free PMC article. Clinical Trial.
Extracranial-Intracranial Bypass and Risk of Stroke and Death in Patients With Symptomatic Artery Occlusion: The CMOSS Randomized Clinical Trial.
Ma Y, Wang T, Wang H, Amin-Hanjani S, Tong X, Wang J, Tong Z, Kuai D, Cai Y, Ren J, Wang D, Duan L, Maimaitili A, Hang C, Yu J, Bai X, Powers WJ, Derdeyn CP, Wu Y, Ling F, Gu Y, Jiao L; CMOSS Investigators. Ma Y, et al. Among authors: wang h. JAMA. 2023 Aug 22;330(8):704-714. doi: 10.1001/jama.2023.13390. JAMA. 2023. PMID: 37606672 Free PMC article. Clinical Trial.
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, Wang K, Liu Y, Wang H, Fu P, Zhang S, Liu Q, Wang S, Huang J, Wang C, Wang S, Wang Y, Zhen L, Zhu X, Wu F, Lin X, Zou J. Wu J, et al. Among authors: wang h. BMC Med. 2022 Dec 27;20(1):498. doi: 10.1186/s12916-022-02708-3. BMC Med. 2022. PMID: 36575513 Free PMC article. Clinical Trial.
1,484 results